Ceapro Inc. Reports Preliminary Results from Clinical Trial Evaluating Oat Beta Glucan in Patients with High Cholesterol Levels November 17, 2021
Ceapro Inc. Provides Update on Development of an Inhalable Therapeutic Using Yeast Beta Glucan Processed with Pressurized Gas eXpanded Technology (PGX-YBG) November 11, 2021
Ceapro Inc. Reports 2021 Second Quarter and Six-Month Financial Results and Operational Highlights August 26, 2021
Ceapro Inc. Enters into Research Collaboration with the Angiogenesis Foundation for Beta Glucan and Avenanthramides August 23, 2021
Ceapro Inc. Expands Collaboration with Montreal Heart Institute (MHI) with New Clinical Study Evaluating Flagship Product, Avenanthramide August 11, 2021
Ceapro Inc. Announces Completion of Patient Enrollment in Clinical Study Evaluating Beta Glucan as a Cholesterol-Lowering Agent May 26, 2021
